Some studies, like ours, have demonstrated that AR+ TNBC cases were associated with a favorable outcome (36, 37), while other studies either failed to report any significant effect of AR expression on survival (38) or reported an aggressive tumor biology, lower pathological complete response rates, and dismal prognosis (39, 40). The gene discussed is AR; the disease is neoplasm.